Safety and efficacy of injectable and oral maropitant, a selective neurokinin 1 receptor antagonist, in a randomized clinical trial for treatment of vomiting in dogs

Maropitant (Cerenia), a selective neurokinin(1) receptor antagonist, was evaluated for safety and efficacy in treatment and prevention of acute vomiting due to various etiologies in dogs in a randomized clinical trial. Two-hundred seventy-eight dogs were enrolled from 29 veterinary hospitals. Two-hundred fifty-two were evaluable for efficacy, while 275 were evaluable for safety. A randomized block design was utilized (three maropitant- and one placebo-treated dog per block). Initial treatment was maropitant at 1 mg/kg body weight (0.45 mg/lb) or an equivalent volume of saline (placebo) administered subcutaneously. On the subsequent 1 to 4 days, maropitant or placebo (dependent on allocation) was administered subcutaneously or orally at approximate 24-h intervals as needed. Oral doses were administered as maropitant tablets using unit dosing to deliver a minimum dose of 2 mg/kg body weight (0.9 mg/lb) or equivalent numbers of similar placebo tablets. Dogs and housing were observed twice daily for evidence of vomiting. Emesis was significantly (P <or= 0.0012) reduced in maropitant-treated dogs as 50% (32/64) of placebo-treated dogs continued to vomit compared to only 21.8% (41/188) of maropitant-treated dogs. Post-treatment clinical signs were consistent with clinical diagnoses and judged not to be treatment related. In this clinical trial, maropitant was safe and effective in reducing emesis due to various etiologies in dogs.

The efficacy of eprinomectin against induced infections of immature (fourth larval stage) and adult nematode parasites in cattle

Eprinomectin is a new endectocide of the avermectin chemical group developed for use in cattle. To establish its effectiveness against Cooperia spp., Dictyocaulus viviparus, Haemonchus contortus, Nematodirus helvetianus, Oesophagostomum radiatum, Ostertagia ostertagi, Trichostrongylus axei and Trichostrongylus colubriformis (immature infections only), six trials were conducted in Europe at two trial sites. In each trial, animals were artificially infected with a number of nematode species and treated with eprinomectin. In three trials, the nematodes were expected to be at the fourth larval stage of development at the time of treatment, and at the adult stage at the time of treatment in the other three trials. When compared with the untreated control groups, efficacy against the adult and immature nematode infections was > 99% for all the nematode species examined. There was no difference in efficacy between groups of animals with clipped hair at the application site, and those with long hair. Subsequent examination of the application sites, both visual and by palpation, showed no gross reactions to the applied treatments.

Eprinomectin: a novel avermectin for control of lice in all classes of cattle

Eight trials were conducted in the United States to determine the efficacy of eprinomectin applied topically against four common species of lice in cattle. In two dose titration trials, eprinomectin dosages of 125 to 750 mcg/kg body weight applied topically were compared to untreated controls. In dose confirmation studies, animals treated topically with eprinomectin applied at the rate of 500 mcg/kg were compared to vehicle-treated controls. Four species of lice were present in these trials: Linognathus vituli, Haematopinus eurysternus, Solenopotes capillatus, all sucking lice, and Damalinia (Bovicola) bovis, the cattle biting louse. Louse counts were made on six to nine predilection sites (the same number of sites in all animals in the same trial) prior to treatment. The same sites were counted again seven days after treatment and weekly thereafter until trial termination eight weeks after treatment. When no lice were found in the predilection sites, a modified whole body search was conducted. Each species of lice was present on at least six animals in each treatment group on at least one counting date in two or more trials. No lice were found on any animal treated topically with eprinomectin at a dosage of > or = 500 mcg/kg after 14 days posttreatment until termination of the trials eight weeks after treatment.

An evaluation of dirlotapide to reduce body weight of client-owned dogs in two placebo-controlled clinical studies in Europe

The clinical efficacy for weight loss and safety of dirlotapide in dogs were evaluated in two multi-centre studies with parallel designs. Overweight, adult dogs (n = 245) of various breeds were randomized to treatment with dirlotapide or placebo in a 2:1 ratio. Dirlotapide was administered orally once daily to dogs at an initial dose of 0.05 mg/kg/day commencing on day 0 and doubled after 14 days. Every 28 days, dogs were examined, weighed, body condition scores (BCS) were recorded, and dose was adjusted to meet weight loss targets. Each study comprised three consecutive phases: weight-loss (up to day 196); weight-stabilization (84 days); and post-treatment (28 days). pre-treatment feeding and exercise regimens were continued during treatment. Dirlotapide-treated dogs showed mean weight loss of 15.9% (study A) and 14.0% (study B) by the end of weight loss phase (up to day 196). Percentage weekly weight losses for dirlotapide were significantly greater than for placebo (P < or = 0.0002). Emesis and diarrhoea were experienced in both treatments but were more frequent with dirlotapide; resolution was spontaneous. BCS improved for 75.7-82.5% of dogs on dirlotapide treatment compared with 15.4-41.4% for placebo. Mean dirlotapide dosage at end of weight-loss phase was 0.38 (study A) and 0.29 (study B) mg/kg initial body weight/day. Dirlotapide was found to be clinically safe and effective in the reduction of body weight in overweight dogs.

Demonstration of the sustained anthelmintic activity of a controlled-release capsule formulation of ivermectin in ewes under field conditions in New Zealand

Ten field trials were conducted in the North and South Islands of New Zealand to evaluate the anthelmintic efficacy of an intraruminal controlled-release capsule formulation of ivermectin. A total of 810 Coopworth, Perendale, Romney or Coopworth ' Romney ewes, weighing on average 42-70 kg, were used. Ewes were either untreated or treated shortly before lambing in late winter-early spring (eight trials) or in late spring (two trials) with an ivermectin controlled-release capsule which delivers ivermectin at 1.6 mg per day for 100 days (minimum dose rate 20microg/kg/day). Bodyweights, faecal nematode egg counts and dag scores were determined before treatment and at about 2 and/or 4, 6 or 8, 10 or 12, 14 and 16 weeks after treatment. Ewes treated with the ivermectin controlled-release capsule gained on average 1.1kg more than untreated sheep over the 16 weeks of the trials, but this difference was not significant (p > 0.10). Before treatment, faecal strongylid egg counts were equivalent (p > 0.10), but at each time point thereafter, egg counts in ivermectin controlled-release capsule treated sheep were significantly lower (p < 0.01; p < 0.05 at Week 2). Dag scores were not different at the start of the trial (p > 0.10), but at the end of the trial ivermectin controlled-release capsule treated ewes had significantly lower scores (p < 0.01) than untreated ewes. These findings indicated that treated animals shed significantly fewer nematode eggs and therefore pasture contamination with nematode eggs should be significantly reduced for at least 112 days. The control of dags should result in reduced direct losses due to the decreased value of dag wool, and indirect losses due to the cost of dagging sheep and the cost associated with the treatment and control of flystrike initiated by dags in the breech area.

Efficacy of a topical formulation of eprinomectin against endoparasites of cattle in New Zealand

Two controlled studies involving 24 cattle were conducted in New Zealand to determine the efficacy of a topical, non-flammable formulation of eprinomectin against induced and naturally acquired nematode infections. In Trial 1, nematode infections were induced on Day -5 with third-stage larvae of Cooperia spp., Haemonchus contortus, Ostertagia ostertagi and Trichostrongvlus colubriformis so that the nematodes would be at the fourth larval stage when the cattle were treated. In Trial 2, cattle had naturally acquired nematode infections as determined by faecal nematode egg counts and larval cultures. The cattle were allocated on Day 0 (Trial 1) or Day 6 (Trial 2) on a stratified random basis according to bodyweight to one of two treatments: untreated control or eprinomectin (0.5% w/v) applied topically at 1 ml/10 kg bodyweight. Necropsies were undertaken on Days 14 and 15 and total nematode counts were done. In Trial 1, cattle treated with eprinomectin had significantly (p < 0.05) fewer Cooperia spp. and O. ostertagi than the controls. Larvae of H. contortus and T. colubriformis did not establish. In Trial 2, cattle treated with eprinomectin had significantly (p < 0.05) fewer of the following parasites than the controls: Haemonchus spp. (adult), Cooperia surnabada (adult), C. oncophora (adult), Cooperia spp. (L,), Ostertagia lyrata (adult), O. ostertagi (adult), Oesophagostomum spp. (adult), T. avei (adult and L1) and Trichuris spp. (adult). Reductions of 100% were observed for Capilfaria spp. (adult), D. viviparus (adult and L,), and Nematodirus helvetianus (adult), but these were not statistically significant (p > 0.05) because four or fewer control animals were infected with these parasites. In Trial 2, efficacies of greater than 99% were observed against all species for which moderate to high burdens occurred in the untreated controls. These findings indicate that eprinomectin in a topical formulation is a highly effective nematocide in cattle.

Efficacy and safety of dirlotapide in the management of obese dogs evaluated in two placebo-controlled, masked clinical studies in North America

Dirlotapide was evaluated in the management of obesity in dogs in two multicenter, clinical studies in North America. A total of 335 obese dogs of various breeds were randomized to dirlotapide or placebo in a 2:1 ratio. Dirlotapide was administered orally once daily to dogs at an initial dose of 0.05 mg/kg, increased after 14 days to 0.1 (study B, label dose) or 0.2 mg/kg (study A) and then adjusted according to individual weight loss at 28-day intervals. Dogs were examined and weighed, and body condition scores (BCSs) were recorded every 28 days. Study A had three consecutive phases: weight loss (16 weeks, day 0-112); weight management (12 weeks); and post-treatment (8 weeks). Study B had a weight loss phase only. For dirlotapide-treated dogs, mean weight loss by day 112 was 11.8-14.0% compared with 3.0-3.9% for placebo (P = 0.0001). In study A, weight losses for dirlotapide were 19.3% after 12 weeks of weight management and 16.7% (regain of 3.4%) by 8 weeks after dirlotapide was discontinued. In both studies, dogs in both treatments had emesis, lethargy, anorexia, diarrhea, and mildly elevated hepatic transaminase activity, that resolved spontaneously with time. These were experienced more frequently with dirlotapide. Improved activity levels and BCS for >50% dogs were reported with dirlotapide. Dirlotapide was safe and effective in the reduction and management of body weight in obese dogs.

Efficacy of ivermectin controlled-release capsules for the control and prevention of nasal bot infestations in sheep

OBJECTIVE

To investigate the therapeutic and prophylactic efficacy of an ivermectin controlled-release capsule against nasal bots (Oestrus ovis) in sheep.

DESIGN

Trial 1--A pen study with controls. Trial 2--A field study with controls.

ANIMALS

Trial 1--Forty Merino wethers with natural infestations of nasal bot were used. Trial 2--One hundred nasal bot-free wethers were used.

PROCEDURE

Trial 1--Ten randomly selected animals were slaughtered and the heads split and examined to confirm bot infestation. Fifteen animals were allocated to untreated controls and 15 to treatment with a controlled-release capsule delivering ivermectin at > or = 20 micrograms/kg/day for 100 days. Twenty-nine days after treatment the sheep were killed and examined for nasal bots. Trial 2--Nasal bot-free sheep were allocated to two groups of 45 animals. One group was untreated the other sheep were treated with capsules as above. The sheep were grazed as a single group exposed to natural challenge from O ovis. Ninety days after treatment the animals were slaughtered and examined for nasal bot infestation.

RESULTS

Trial 1--Live O ovis larvae were recovered from 60% of control sheep. No live larvae were collected from treated sheep. Trial 2--Forty-one percent of untreated sheep harbored nasal bot infestations. No live larvae were collected from any treated animal.

CONCLUSION

Treatment with a single ivermectin controlled release capsule was 100% effective against existing infestations of O ovis and as a prophylactic treatment for this parasite.

Effect of simulated rain, coat length and exposure to natural climatic conditions on the efficacy of a topical formulation of eprinomectin against endoparasites of cattle

A series of five controlled studies involving 114 cattle were conducted in Australia, North America and the United Kingdom to examine the effect of simulated rain, coat length and exposure to natural climatic conditions, on the efficacy of a topical formulation of eprinomectin against nematode parasites of cattle. In all trials infections were induced with a range of bovine nematode species and treatment was applied when the majority of nematodes were mature. In one study, simulated rain was applied to cattle ending one hour before treatment or beginning one, three or six hours after treatment. In a second study cattle had short (1 cm) or long (3-6 cm) haircoats at the time of treatment. Three other studies were conducted using cattle housed indoors or exposed to various natural climatic conditions. Nematode counts were determined using standard techniques and the efficacy of treatment was assessed relative to vehicle-treated controls. Regardless of the timing of simulated rain relative to treatment, eprinomectin was at least 99.9% effective (P < 0.01) against Haemonchus placei, Ostertagia ostertagi. Trichostrongylus axei and Cooperia spp. There were also no differences (p > 0.10) in efficacy between treatment administered to dry or wet cattle, or treatment administered before or after simulated rainfall. Efficacies against O. ostertagi, T. axei, Cooperia ancophora and Dictyocaulus viviparus were > 99.5% (p < 0.01) regardless of the length of the haircoat at the application site. Exposure of treated cattle to sunshine and precipitation had no effect on anthelmintic efficacy (p > 0.10) with efficacies of greater than 99.5% being maintained against H. placei, O. ostertagi (adult and fourth-stage larvae), T. axei, Cooperia spp., Nematodirus helvetianus (adult and inhibited fourth-stage larvae) and Oesophagostomum radiatum. These findings indicate that eprinomectin (500 micrograms/kg) in a topical formulation is a safe and highly effective nematocide for cattle regardless of their coat length and this high level of efficacy is maintained in cattle exposed to a wide variety of climatic conditions.

GM2 Gangliosidosis in Shiba Inu Dogs with an In-Frame Deletion in HEXB

Consistent with a tentative diagnosis of neuronal ceroid lipofuscinosis (NCL), autofluorescent cytoplasmic storage bodies were found in neurons from the brains of 2 related Shiba Inu dogs with a young‐adult onset, progressive neurodegenerative disease. Unexpectedly, no potentially causal NCL‐related variants were identified in a whole‐genome sequence generated with DNA from 1 of the affected dogs. Instead, the whole‐genome sequence contained a homozygous 3 base pair (bp) deletion in a coding region of HEXB. The other affected dog also was homozygous for this 3‐bp deletion. Mutations in the human HEXB ortholog cause Sandhoff disease, a type of GM2 gangliosidosis. Thin‐layer chromatography confirmed that GM2 ganglioside had accumulated in an affected Shiba Inu brain. Enzymatic analysis confirmed that the GM2 gangliosidosis resulted from a deficiency in the HEXB encoded protein and not from a deficiency in products from HEXA or GM2A, which are known alternative causes of GM2 gangliosidosis. We conclude that the homozygous 3‐bp deletion in HEXB is the likely cause of the Shiba Inu neurodegenerative disease and that whole‐genome sequencing can lead to the early identification of potentially disease‐causing DNA variants thereby refocusing subsequent diagnostic analyses toward confirming or refuting candidate variant causality.

Efficacy of an ivermectin controlled-release capsule against nematode and arthropod endoparasites in sheep

Five controlled trials were conducted in Germany or in the United Kingdom, using 74 female sheep of merino or Dorset horn breeds, to evaluate the efficacy of an ivermectin controlled-release capsule against naturally acquired or induced infections of gastrointestinal nematodes, lungworms and nasal bot larvae and against incoming infections with gastrointestinal and pulmonary nematodes. Half of the animals were treated with one ivermectin controlled-release capsule that delivered ivermectin at the rate of 1.6 mg per day for 100 days while the other half remained untreated. Parasites were counted 21, 28, 35 or 56 days after administration of the capsule. The treatment was highly effective (> or = 99 per cent) against established parasites of the following species: Haemonchus contortus (adults and fourth-stage larvae), Ostertagia circumcincta, O pinnata, O trifurcata, Ostertagia species fourth-stage larvae, Trichostrongylus axei, T colubriformis, T vitrinus, Cooperia curticei, Nematodirus battus, N filicollis, Strongyloides papillosus, Chabertia ovina, Oesophagostomum venulosum, Trichuris ovis, Tr skrjabini, Dictyocaulus filaria, Protostrongylus rufescens and Oestrus ovis (larvae). The treatment prevented the establishment of the gastrointestinal nematodes H contortus, O circumcincta, T axei, T colubriformis, C curticei, N battus, N filicollis, Ch ovina, Oe vennulosum and the establishment of the lungworm D filaria by > 99 per cent compared with untreated controls (P < or = 0.01).

Demonstration of the sustained anthelmintic efficacy of a controlled-release capsule formulation of ivermectin in weaner lambs under field conditions in New Zealand

Ten field trials were conducted in the North and South Islands of New Zealand to evaluate the anthelmintic efficacy and production responses attributable to treatment of weaner lambs with an intra-ruminal controlled-release capsule formulation of ivermectin. A total of 800 Coopworth, Perendale and Romney lambs weighing on average 20.8-34.8 kg were used. Lambs were either untreated or treated shortly after weaning with an ivermectin controlled-release capsule which delivers ivermectin at 0.8 mg per day for 100 days (minimum dose rate 20 microg/kg/day). Bodyweights, faecal nematode egg counts and dag scores (assessment of faecal soiling in the breech area) were determined before treatment and at about 4,8, 12, 14 and 16 weeks after treatment. Sheep treated with the Ivermectin capsule gained significantly more weight (11.6 kg) over the 16 weeks of the trials compared to untreated sheep (7.3 kg) (p < 0.01). Before treatment, faecal strongylid and Nematodirus spp. egg counts were equivalent (p > 0.10) but, at each time point thereafter, egg counts in ivermectin capsule-treated sheep were significantly lower (p < 0.01 or p < 0.05). Dag scores were not different at the start of the trial (p > 0.10), but at the end of the trial control sheep had significantly greater dags (p < 0.05) than sheep treated with the ivermectin capsule. These findings indicate that treated animals contributed significantly fewer nematode eggs to the contamination of pasture and therefore pasture contamination should be significantly reduced for at least 112 days. The productivity of the ivermectin capsule-treated sheep over the I6 weeks of the trials was also significantly increased compared to salvage-treated controls. Furthermore, the presence of dags, which predispose sheep to blowfly strike in the breech area and result in production losses due to the costs of dagging and downgrading of breech wool, were also significantly (p < 0.05) reduced in the ivermectin capsule-treated sheep.

Control of gastro-intestinal parasitism in sheep with ivermectin delivered via an intraruminal controlled-release capsule

The efficacy of ivermectin delivered by an intraruminal controlled-release capsule against gastro-intestinal nematodes of sheep was evaluated under controlled conditions. In seven Australian studies involving 170 Merino or Merino x Border Leicester sheep, intraruminal capsules developed for 20-40 kg or 40-80 kg sheep, and delivering 0.8 or 1.6 mg of ivermectin/day respectively for 100 days (minimum dose 20 microg/kg/day), were evaluated. Studies were designed to test the therapeutic efficacy against naturally acquired and induced infections treated at the adult and fourth larval stage, and the prophylactic efficacy against naturally acquired and induced infections with third stage infective larvae. The predominant pathogenic nematodes of sheep were represented. Two studies included known benzimidazole- and levamisole-resistant nematode strains. Sheep were necropsied for total nematode counts 21-8.5 days after treatment. The efficacy of the ivermectin controlled-release capsule was generally >99% against all nematode species tested, including those confirmed to be benzimidazole- and levamisole-resistant. High therapeutic activity was demonstrated against existing adult and fourth larval stage nematode infections at the time of treatment, and high prophylactic efficacy was shown against incoming third stage larvae of all species and strains tested.

Field trials to confirm the efficacy of ivermectin jetting fluid for control of blow fly strike in sheep

Fifty-two field trials, involving 14,296 sheep, were conducted to confirm the efficacy and safety of ivermectin jetting fluid against blow fly strike in sheep in Australia. A total of 7143 sheep were treated by hand-jetting with a 0.03 mg ml-1 solution of ivermectin, while 7153 sheep were untreated controls. The percent reduction in the cumulative incidence of strikes within the treatment area for ivermectin-treated sheep in comparison with untreated controls, was 96.5%, 95.8% and 93.5% at 10, 12 and 13/14 weeks after treatment, respectively. There were no adverse reactions to treatment.

Efficacy of ivermectin in a controlled-release capsule for the control of breech strike in sheep

OBJECTIVE

To investigate the efficacy of ivermectin in an intraruminal controlled-release capsule (CRC) against blowfly strike.

DESIGN

Pen and field trials with controls.

ANIMALS

Pen studies: Two breech strike trials involving 60 Romney and 60 Merino sheep. One body strike trial using 100 Merino sheep. Field trials: Eight trials in New Zealand used 1000 Romney and Romney-cross sheep. Fifty Merino lambs in one trial in Australia.

PROCEDURE

Pen studies: Sheep were allocated to two equal groups. One was not treated, the other sheep received a CRC that delivered ivermectin at > or = 20 micrograms/kg/day for 100 days. In the breech strike trials, each animal was given an oral laxative 2 days before exposure to adult Lucilia cuprina. In the body-strike trial, the sheep sheep were kept wet to increase susceptibility prior to the release of blowflies. Field trials: Fifty or 200 sheep allocated to equal groups of nontreated or treated with the CRC and grazed at pasture exposed to natural blowfly challenge.

RESULTS

Pen studies: Breech strikes developed in 24 of 60 controls but in none of 60 CRC-treated sheep. There was a 35% reduction in the number of CRC-treated sheep struck on the body. Field trials: The average number of breech strikes in CRC-treated sheep was reduced by 86% (P < 0.001). The number of body strikes in the treated groups was a reduced by 27% (P < 0.05).

CONCLUSION

The ivermectin CRC is a useful aid in controlling breech strike, but provides only moderate reduction in the incidence of body strike.

Field trials evaluating ivermectin controlled-release capsules for weaner sheep and for breeding ewes

OBJECTIVE

To confirm the efficacy of ivermectin released from a controlled-release capsule administered to young sheep and to breeding ewes under field conditions.

DESIGN

Randomised field trials.

PROCEDURE

In each of ten field trials 25 weaned lambs were treated with ivermectin controlled-release capsules and 25 remained untreated. Eight similar field trials were conducted using adult ewes. Efficacy against infections of gastrointestinal nematodes was assessed by faecal egg counts and faecal larval culture. Body weights were recorded and faecal soiling of the breech wool (dags) was assessed.

RESULTS

Nematode faecal egg counts in the two groups were not different (P = 0.13) before treatment in the weaner trials or before treatment in the ewe trials (P = 0.49), but thereafter eggs in the untreated sheep persisted, whereas counts in sheep given capsules were negligible (P < or = 0.01). In the weaner trials, dag scores for the two groups were not different at the start of the trials (P = 0.18) but at the end, untreated sheep had significantly more dags (P = 0.04) than treated sheep. In the ewe trials, dag scores remained low in both groups. Weaners treated with the capsule gained 1.4 kg (95% CL: 0.7, 3.1) more weight over the 16 week trial period compared to untreated weaners (P = 0.01). Both groups of ewes lost weight as a result of parturition but the mean loss by week 16 was greater for untreated (3.7 kg) (95% CL: -5.1, -2.2) than for treated ewes (1.8 kg) (95% CL: -3.3, -0.4). The mean change in ewe body weight for the two groups was however not significant (P = 0.07). Differentiation of nematode larvae recovered from cultures of faeces from untreated animals indicated that the capsules were effective against the common parasites of sheep.

CONCLUSION

The capsule was efficacious against gastrointestinal nematodes judging from faecal egg counts. It has the potential to significantly reduce contamination of pasture with nematode eggs. Treated weaners had less dags for 16 weeks and gained more weight than untreated weaners.

Efficacy of ivermectin in a controlled release formulation against Psoroptes ovis (Hering, 1838) gervais, 1841 (Acari: Psoroptidae) on sheep

Three trials including 42 sheep were conducted in Brazil or Germany to evaluate the therapeutic (two trials) and prophylactic (one trial) efficacy of an ivermectin controlled release capsule (CRC) against Psoroptes ovis infestation. In one therapeutic trial naturally infested sheep were used while in the other trials infestations were experimentally induced. In each trial half of the animals were treated on Day 0 with one ivermectin controlled release capsule that delivers ivermectin at a rate of 1.6 mg/day for approximately 100 days, that is 20 mcg/kg/day to a 80 kg animal, while the other half remained untreated. In both therapeutic trials mites were counted in skin scrapings and their presence was recorded at predilection sites one day before treatment and at weekly intervals from Day 7 to Day 56. In the trial conducted to evaluate the prophylactic efficacy the sheep were experimentally infested with P. ovis 21 and 28 days post-treatment and mites were counted and recorded at predilection sites on Days 42, 49 and 56. The ivermectin controlled release capsule was completely effective in eliminating the P. ovis mites within 28 days of administration and it prevented the establishment of an infestation of P. ovis induced 21 and 28 days after administration.

Efficacy and safety of ivermectin applied topically to cattle under field conditions in Australia

Fifteen controlled field trials were conducted to evaluate the efficacy against gastrointestinal nematodes and safety of ivermectin when applied topically to cattle in Australia. Three hundred and fifty-one cattle received ivermectin, and 88 were untreated controls. The trials were conducted in 3 States and included a variety of cattle breeds and environmental conditions. Faecal samples were collected before treatment and 11 to 14 days after treatment for nematode egg counts. Data from these trials show that under Australian conditions, ivermectin applied along the mid line of the back from the withers to the sacral region at a dose rate of 500 mcg/kg body weight, effectively controlled gastrointestinal nematode infections, and did not produce unacceptable adverse reactions in the animals.

An ivermectin tablet for sheep: efficacy against gastro-intestinal nematodes and a bioavailability comparison with a liquid ivermectin formulation

An ivermectin tablet for oral administration to sheep was developed for use in countries where it is customary to treat sheep with anthelmintic tablets. Tablets require no special administration equipment, and offer convenience for storage and transport. The ivermectin tablet, which delivers 10 mg of ivermectin (200 micrograms kg-1 in a 50 kg sheep), had similar bioavailability to a liquid formulation of ivermectin (IVOMEC Liquid for Sheep) as determined by peak plasma ivermectin concentrations and area under the concentration curve in plasma (P > 0.10). In dose confirmation trials in which nematode infections were induced in helminth-naive sheep, animals treated with the ivermectin tablet had significantly fewer adult and fourth-stage larval nematodes than untreated control sheep (P < 0.01) with efficacies > 99% against all nematode species tested. In six field trials evaluating the efficacy of the ivermectin tablet in 240 Merino sheep, the reductions in faecal nematode egg counts ranged between 98 and 100%, as determined by comparison of pre- and post-treatment counts for the ivermectin-treated group.

Therapeutic and prophylactic efficacy of the Ivomec SR Bolus against nematodes and Psoroptes ovis in cattle weighing more than 300 kg at the time of treatment

Three trials using 50 European breed cattle were conducted to evaluate the therapeutic and prophylactic efficacy of the Ivomec SR Bolus against nematodes (2 trials) and Psoroptes ovis (1 trial) in cattle weighing more than 300 kg at the time of treatment. The Ivomec SR Bolus proved to be highly effective against economically important gastrointestinal and pulmonary nematodes (Ostertagia ostertagi, Trichostrongylus axei, Cooperia punctata, Oesophagostomum radiatum, Dictyocaulus viviparus) and improved the rate of weight gain significantly. P. ovis was eliminated from cattle treated with an Ivomec SR Bolus. The treatment also provided prophylaxis against an infestation of P. ovis and increased the weight gain of cattle infested with P. ovis.

Persistent anthelmintic activity of abamectin injection in cattle

The duration of the anthelmintic activity of abamectin administered by subcutaneous injection at 200 microg/kg was determined using induced infections of Haemonchus placei, Ostertagia ostertagi, Cooperia spp., and Oesophagostomum radiatum in cattle. Twenty-four Friesian calves, raised under worm-free conditions, were assigned to four groups of six animals using a randomised block design based on bodyweight. One group acted as untreated controls and the other three were treated with abamectin 14, 10 or 7 days before infection. At slaughter, 50-52 days after treatment (36-38 days after infection), efficacy was greater than 98-99% against all the parasite species for the groups challenged 10 and 7 days after treatment, whereas no significant activity could be demonstrated 14 days after treatment.

The efficacy of ivermectin jetting fluid for control of blowfly strike on sheep under field conditions

Seventeen trials involving 5737 sheep were conducted to test the efficacy of ivermectin jetting fluid (30 ppm in water) for the control of blowfly strike when applied to sheep either by standard hand jetting or through an automatic jetting race. Sheep were observed for up to 14 weeks after treatment and all strikes recorded. The level of fly challenge varied between trials, resulting in strike rates in untreated sheep ranging between 0 and 94%. At 12 weeks after treatment there were 93% fewer strikes in hand jetted sheep and 84% fewer strikes in machine jetted sheep when compared with untreated sheep. At this time and point there was a 90%, 86% and 93% reduction in poll, body and breech strikes, respectively, when hand jetting was used, whereas machine jetting reduced poll, body, breech and pizzle strikes by 84%, 81%, 79% and 100%, respectively.